TTOO 1.40 On June 30, 2020, T2 Bioystems, Inc. (the “Company”) announced the US launch of its COVID-19 molecular diagnostic test, the T2SARS-CoV-2 Panel, after validation of the test meeting the United States Food and Drug Administration’s (FDA’s) requirements for an Emergency Use Authorization (EUA). On July 1, 2020, the Company submitted an EUA request to the FDA for the T2SARS-CoV-2 Panel.
News 
Market Data 
Discover 
